Fertility and Sterility
Volume 94, Issue 4 , Pages 1195-1201, September 2010

Suppression of ovarian function by a combined oral contraceptive containing 0.02 mg ethinyl estradiol and 2 mg chlormadinone acetate given in a 24/4-day intake regimen over three cycles

  • Jürgen Spona, Ph.D.

      Affiliations

    • Vitalogic GmbH, Vienna, Austria
    • Corresponding Author InformationReprint requests: Jürgen Spona, Ph.D., Vitalogic GmbH, Czerningasse 10, 1020 Vienna, Austria (FAX: 43-1-877-91539).
    • ,
  • Natascha Binder, Ph.D.

      Affiliations

    • Grünenthal GmbH, Aachen, Germany
    • ,
  • Kornelia Höschen, M.Sc.

      Affiliations

    • Grünenthal GmbH, Aachen, Germany
    • ,
  • Wilfried Feichtinger, Ph.D.

      Affiliations

    • Institute for Sterility Treatment, Vienna, Austria

Received 17 April 2009; received in revised form 22 June 2009; accepted 25 June 2009. published online 25 August 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 J.S. has nothing to disclose. N.B. has nothing to disclose. K.H. has nothing to disclose. W.F. has nothing to disclose.

 This study was designed, conducted and funded by Grünenthal GmbH. The Principle Investigator was Wilfried Feichtinger, M.D., and the Scientific Advisor was Jürgen Spona, Ph.D.

PII: S0015-0282(09)01431-9

doi:10.1016/j.fertnstert.2009.06.057

Fertility and Sterility
Volume 94, Issue 4 , Pages 1195-1201, September 2010

Article Tools

* Image Usage & Resolution